YMTracker DRIPCalc v2 Launch sale

NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

KROS | NASDAQ

$11.73 -$0.22 | -1.84%

TREND SIGNAL: Signal available — unlock to view

Signal available — unlock to view

|2026-10-09

Add to favoritesFavorite

Company Overview:

Market Cap: $236.93M

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $9.69 - $22.55

6.5 Year KROS Performance Metrics:

Total Return (with DRIP): -41.6% (-7.94% CAGR)

Total Return (no DRIP): -41.6% (-7.94% CAGR)

Share Price: -41.6% (-7.94% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $5,842

Total Return $ (with DRIP): -$4,158

KROS Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

KROS Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Get 3 Months Free with Annual Plan

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

Combined 55% Lifetime Discount

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

Combined 55% Lifetime Discount

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

Combined 55% Lifetime Discount

KROS Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

KROS - Revenue

KROS Revenue CAGR:1Y: 0.00%2Y: 2,115.91%5Y: 183.05%10Y: 0.00%

KROS - Earnings Per Share (EPS)

KROS EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

KROS - Net Income

🔓 See the full chart40% off right now · 7-day free trial

KROS Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

KROS - EBITDA

🔓 See the full chart40% off right now · 7-day free trial

KROS EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

KROS - Free Cash Flow

🔓 See the full chart40% off right now · 7-day free trial

KROS Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

KROS - Free Cash Flow / Share

🔓 See the full chart40% off right now · 7-day free trial

KROS Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

KROS - Operating Income

🔓 See the full chart40% off right now · 7-day free trial

KROS Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

KROS - Gross Profit

🔓 See the full chart40% off right now · 7-day free trial

KROS Gross Profit CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

KROS - Shares Outstanding

🔓 See the full chart40% off right now · 7-day free trial

KROS Shares Outstanding CAGR:1Y: -51.25%2Y: -25.94%5Y: -3.21%10Y: 0.00%

KROS - Share Buybacks

🔓 See the full chart40% off right now · 7-day free trial

KROS Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

KROS - Stock-Based Comp

🔓 See the full chart40% off right now · 7-day free trial

KROS Stock-Based Comp CAGR:1Y: -37.05%2Y: -21.77%5Y: 13.55%10Y: 0.00%

KROS - Expenses

🔓 See the full chart40% off right now · 7-day free trial

KROS Expenses CAGR:1Y: -78.47%2Y: -29.29%5Y: -21.20%10Y: 0.00%

KROS - Revenue vs Net Income

🔓 See the full chart40% off right now · 7-day free trial

KROS - EPS vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

KROS - EPS vs PE Ratio

🔓 See the full chart40% off right now · 7-day free trial

KROS - FCF vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

KROS - FCF vs Stock Based Comp

🔓 See the full chart40% off right now · 7-day free trial

KROS - Cash & Debt

🔓 See the full chart40% off right now · 7-day free trial

KROS - Revenue by Segment

🔓 See the full chart40% off right now · 7-day free trial

KROS Revenue CAGR:1Y: 0.00%2Y: 2,115.91%5Y: 183.05%10Y: 0.00%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

KROS - REVENUE: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

KROS Actual Revenue CAGR:1Y: 0.00%2Y: 2,115.91%5Y: 183.05%10Y: 0.00%

KROS - EPS: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

KROS Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

KROS - NET INCOME: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

KROS Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

KROS - EBITDA: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

KROS Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

KROS - Net Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

KROS Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

KROS - Gross Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

KROS Gross Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

KROS - Price to Earnings

🔓 See the full chart40% off right now · 7-day free trial

KROS Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

KROS - Price To Sales Ratio

🔓 See the full chart40% off right now · 7-day free trial

KROS Price To Sales Ratio CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

KROS - Return on Capital Employed

🔓 See the full chart40% off right now · 7-day free trial

KROS Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

KROS - Return on Invested Capital

🔓 See the full chart40% off right now · 7-day free trial

KROS Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Projected Future Returns & Dividends for KROS

Based on past 6.5-year performance, here are KROS growth metrics:

Share price CAGR of -7.94%
Dividend CAGR of +0%

Using KROS CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	KROS (DRIP)	KROS - No DRIP
Current Price	$11.73	$11.73
Start Shares	852.51	852.51
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	852.51	852.51
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$5.13	$11.73
Total Dividends	$0	$0
Final Value	$4,373	$10,000

Estimated Future Value + Dividends - KROS

NOTE: Above numbers are our estimate based on KROS's Dividend and Price CAGR over past 6.5 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Get 3 Months Free with Annual Plan

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

Combined 55% Lifetime Discount

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

Combined 55% Lifetime Discount

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

Combined 55% Lifetime Discount

Company Info

Keros Therapeutics, Inc. (KROS) had its IPO on 2020-04-08, and is traded on NASDAQ stock exchange.

Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.

KROS website: https://www.kerostx.com

Get Full Access to All Reports with DRIPCalc PRO

Get 3 Months Free with Annual Plan

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

Combined 55% Lifetime Discount

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

Combined 55% Lifetime Discount

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

Combined 55% Lifetime Discount

Loading signals…

DCF Model — KROS

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $11.73

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →

× Free Portfolio Tracker

Own KROS? See every dividend it's paid you

Add your KROS shares to a free account and every payment you've received is listed — dated, in dollars — with reinvested shares counted and monthly totals. Room for 4 more stocks.

✓Every KROS dividend you've received, dated, with the amount
✓Reinvested (DRIP) shares counted for you
✓Monthly totals across up to 5 stocks

Add KROS free →

Free plan · up to 5 holdings